Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

NCT05492578 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05492578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05492578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.
Lead sponsor
Sanofi
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 22, 2022
Completion date
January 22, 2029
Enrollment
1,856 (actual)
Sites
392

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis atopic